Insilico Says A.I.-Generated Rentosertib Cut Aging Markers on 6 Clocks
Updated
Updated · The New York Times · Sep 7
Insilico Says A.I.-Generated Rentosertib Cut Aging Markers on 6 Clocks
3 articles · Updated · The New York Times · Sep 7
Summary
Nature Biotechnology published early clinical-trial data showing rentosertib lowered biological age markers across six A.I.-based “aging clocks,” giving Insilico Medicine a new longevity claim for the drug.
The finding came from a trial already reported last year as suggesting benefit in chronic lung disease, with the same dataset now reanalyzed for aging-related signals.
Rentosertib’s molecular structure was generated with A.I., making the study a notable test of whether artificial-intelligence tools can produce drugs with measurable human effects beyond a single disease target.
The result remains preliminary: the drug is still years from possible approval, and Insilico has not tested anti-aging effects in healthy people while scientists still debate how informative aging clocks really are.